

Helix 11 Dynamics Is Critical for Constitutive Androstane Receptor Activity

Edward Wright,^{1,3} Scott A. Busby,^{2,3} Sarah Wisecarver,¹ Jeremy Vincent,¹ Patrick R. Griffin,² and Elias J. Fernandez^{1,*}

¹Biochemistry, Cellular and Molecular Biology, University of Tennessee, Knoxville, TN 37996, USA

²Department of Molecular Therapeutics, The Scripps Research Institute, 130 Scripps Way, Jupiter, FL 33458, USA

³These authors contributed equally to this work

*Correspondence: elias.fernandez@utk.edu

DOI 10.1016/j.str.2010.11.008

SUMMARY

The constitutive androstane receptor (CAR) transactivation can occur in the absence of exogenous ligand and this activity is enhanced by agonists TCPOBOP and meclizine. We use biophysical and cell-based assays to show that increased activity of CAR(TCPOBOP) relative to CAR(meclizine) corresponds to a higher affinity of CAR(TCPOBOP) for the steroid receptor coactivator-1. Additionally, steady-state fluorescence spectra suggest conformational differences between CAR(TCPOBOP):RXR and CAR(meclizine):RXR. Hydrogen/deuterium exchange (HDX) data indicate that the CAR activation function 2 (AF-2) is more stable in CAR(TCPOBOP):RXR and CAR(meclizine):RXR than in CAR:RXR. HDX kinetics also show significant differences between CAR(TCPOBOP):RXR and CAR(meclizine):RXR. Unlike CAR(meclizine):RXR, CAR(TCPOBOP):RXR shows a higher overall stabilization that extends into RXR. We identify residues 339–345 in CAR as an allosteric regulatory site with a greater magnitude reduction in exchange kinetics in CAR(TCPOBOP):RXR than CAR(meclizine):RXR. Accordingly, assays with mutations on CAR at leucine-340 and leucine-343 confirm this region as an important determinant of CAR activity.

INTRODUCTION

Nuclear receptors (NRs) are multidomain transcription factors that play a vital role in growth, development, and homeostasis (Mangelsdorf et al., 1995). These proteins consist of an N-terminal activation function-1 (AF-1), a central DNA-binding domain (DBD), and a C-terminal ligand-binding domain (LBD) which encompasses the activation function-2 (AF-2). X-ray structures of all NR LBDs determined to date exhibit a common three-dimensional fold. The C-terminal LBD encloses the ligand-binding pocket (LBP) within a 12 α helix framework (Moras and Gronemeyer, 1998; Wurtz et al., 1996). The ultimate helix H12, also the ligand-dependent activation function 2 (AF-2) of the LBD, plays a critical role in the recruitment of coactivator and corepressor molecules. NRs utilize a common agonist-mediated repositioning of helix H12 to generate the coactivator-binding

groove (Glass et al., 1997). However, differences in levels of transcriptional activity in response to various agonists of the same receptor suggest that agonists can fine-tune the conformation of the coactivator-binding groove and consequently the affinity of the activated receptor for coactivator proteins (Bourguet et al., 2000; Gangloff et al., 2001; Oberfield et al., 1999).

CAR plays key roles in the clearance of xenobiotics (Sonoda et al., 2003; Wei et al., 2000) and endogenous toxins such as bilirubin (Huang et al., 2003). In addition, this protein has pharmacological importance due to its role in drug-to-drug interactions (Chang and Waxman, 2006). Also, prolonged CAR activation has been observed to enhance the progression of liver cancer (Huang et al., 2005). For optimal function, CAR heterodimerizes with the retinoid X receptor (RXR) and the CAR:RXR heterodimer can transactivate retinoic acid response elements (RAREs) in an apparent ligand-independent manner (Baes et al., 1994; Choi et al., 1997). Transactivation by murine CAR is further enhanced by agonist ligands such as 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) (Tzamelis et al., 2000) and 1-[(4-chlorophenyl)(phenyl)methyl]-4-(3-methylbenzyl)piperazine (meclizine) (Huang et al., 2004) (Figure 1A). Activated CAR recruits coactivator proteins such as the steroid receptor coactivator-1 (SRC1) by interacting specifically with receptor interacting domain (RID) 2 of SRC1 (Dussault et al., 2002). Androstane metabolites such as androstenediol (5 α -androst-16-en-3 α -ol) have been identified as the physiological inverse agonist ligands of murine CAR (Forman et al., 1998). Androstenediol binds to the CAR ligand-binding domain (LBD) where it displaces helix H12 (AF2) from the active-state conformation required to recruit coactivator proteins (Shan et al., 2004). Incidentally, meclizine is also a ligand for the human CAR isoform, where it functions as an inverse agonist (Huang et al., 2004).

Here, we report a comparative study of the role of two agonists of murine CAR. We compare CAR transactivation and coactivator binding affinities in response to the agonists TCPOBOP and meclizine. Further, we utilize fluorescence spectroscopy, HDX and site-specific mutagenesis to identify distinct CAR alterations in conformational dynamics induced upon binding either TCPOBOP or meclizine.

RESULTS

Comparing Transactivation and Coactivator Binding by CAR(TCPOBOP) and CAR(meclizine)

Meclizine has been identified as an mCAR agonist in a high-throughput screen and confirmed by a reporter gene assay using




Figure 1. Comparison of the Two CAR Ligands Used in This Study
 (A) The chemical structures of CAR and TCPOBOP are shown.
 (B) TCPOBOP is a more potent agonist in cell-based reporter gene assays using the β RE response element. The data is shown in relative luciferase units (RLU).
 (C) TCPOBOP promotes higher affinity for coactivator than meclizine in ITC experiments.

the LXRE response element in HepG2 cells (Huang et al., 2004). Also, in these experiments TCPOBOP is observed to exert a stronger agonist response from CAR than meclizine. Reporter gene assays with a second response element, β RE in CV-1 cells, confirm that TCPOBOP induces higher CAR transactivation than meclizine, independent of the DNA hormone response element or cell line (Figure 1B). To compare the recruitment of coactivator protein by CAR(TCPOBOP):RXR and CAR(meclizine):RXR, we measured SRC1 binding to ligand-bound CAR using ITC. Quantitative analyses of binding isotherms show that at saturating concentrations of meclizine the affinity

for coactivator is less than CAR(TCPOBOP) (Figure 1C). The thermodynamic parameters for recruitment of SRC1 NR2 peptide are presented in Table 1. All three forms of the heterodimer have similar favorable enthalpy change (ΔH). The thermodynamic basis for the difference in affinity is the larger unfavorable entropy change (ΔS) observed in SRC1 binding to CAR(meclizine):RXR compared with SRC1 binding to CAR(TCPOBOP):RXR.

Conformational Differences within the CAR:RXR, CAR(TCPOBOP):RXR, and CAR(meclizine):RXR Complexes

Comparative binding data shows that CAR(TCPOBOP):RXR exhibits a stronger affinity for SRC1 coactivator peptide than the CAR(meclizine):RXR complex. To determine a structural basis for these results, we utilized steady-state quenching of intrinsic tryptophan fluorescence of CAR:RXR to monitor changes in conformation upon ligand binding. Upon titrating TCPOBOP into the CAR:RXR heterodimeric LBD complex, there is a dose-responsive decrease in fluorescence of this protein complex. Since the CAR LBD sequence does not contain any tryptophan residues and an excitation wavelength of 295 nm is chosen to minimize the contribution from tyrosine residues, the TCPOBOP-induced conformational changes are transmitted from CAR across the CAR:RXR interface to the two tryptophan residues on RXR (Figures 2A and 2B). However, these conformational changes do not appear to significantly affect 9-*cis*-retinoic acid (9c) binding to CAR:RXR (see Figure S1 available online). In addition, we determined the effect of ligand binding on each tryptophan on RXR by titrating TCPOBOP into CAR:(W282F)RXR and CAR:(W305F)RXR (Figure S2). There is a strong dose-dependent increase in tryptophan quenching induced by TCPOBOP on the CAR:(W282F)RXR mutant but no significant response to the ligand by the CAR:(W305F)RXR mutant (Figure S2A). This suggests that while W305 in RXR is within the allosteric pathway that is regulated by TCPOBOP, the environment of W282 does not undergo significant changes in the presence of TCPOBOP.

Curiously, titrations of meclizine into CAR:RXR result in no significant changes in the fluorescence spectra (Figure 2B). Therefore, although both TCPOBOP and meclizine function as mCAR agonists, the molecular mechanisms of CAR(TCPOBOP) and CAR(meclizine) transactivation are not identical.

To identify specific structural features in CAR:RXR that rearrange upon ligand binding and to distinguish between CAR(TCPOBOP):RXR and CAR(meclizine):RXR, we performed comprehensive differential, solution phase amide HDX MS experiments on the CAR:RXR, CAR(TCPOBOP):RXR and CAR(meclizine):RXR LBD complexes. For each receptor(ligand) complex, differential HDX kinetics are determined by comparing the kinetics of individual peptic peptides derived from the complex to the corresponding peptic peptides generated from the unliganded receptor.

Amide exchange kinetics of peptides representative of 76 regions of the CAR LBD within CAR:RXR and CAR(TCPOBOP):RXR were compared for the two protein complexes (Figure 3A; Figure S3A). From the same data sets, HDX kinetics were determined and compared for peptides representative of 84 segments of RXR in the CAR:RXR and CAR(TCPOBOP):RXR complexes (Figure 3B; Figure S3B). We observe statistically

Table 1. Thermodynamic Parameters for SRC1 Peptide Binding to CAR:RXR in the Presence of Indicated Ligands

Ligand	K_d (μM)	ΔH (kcal/mol)	$-T\Delta S$ (kcal/mol)	ΔG (kcal/mol)	n
TCPOBOP ^a	0.60 ± 0.10	-10.0 ± 0.3	1.5	-8.5	0.98 ± 0.07
Meclizine	0.91 ± 0.14	-9.9 ± 0.3	1.7	-8.2	0.95 ± 0.08
None ^a	4.9 ± 0.7	-10.0 ± 0.4	2.8	-7.2	1.03 ± 0.06

Determined at 25°C and pH 7.2 as described in [Experimental Procedures](#). The reported values are the average of at least three experiments and the errors are the standard deviation.

^aOriginally reported by [Wright et al. \(2007\)](#).

significant changes in HDX kinetics in three specific subdomains of CAR. Peptides encompassing helices H2' and H2'' as well as parts of helix H3 (residues 143–178) show significant protection from exchange in CAR(TCPOBOP):RXR compared with CAR:RXR. In addition, there are substantial reductions in exchange kinetics within the sequences that comprise helix H4 and parts of the β sheet, helix H6 and helix H7 (residues 199–

210 and 228–249). The most significant reductions in HDX behavior of the CAR(TCPOBOP) complex are seen within the region encompassing helices H10, H11, and H12 (residues 327–358). These results reflect the extensive network of hydrophobic interactions between TCPOBOP and CAR that stabilize AF-2 in the active conformation as observed in the structure of CAR(TCPOBOP):RXR(9c) ([Suino et al., 2004](#)). In this structure, the TCPOBOP A-ring is sandwiched between CAR Y234 and CAR F227 and the C-ring is sandwiched between CAR Y336 and F244. The C-ring of TCPOBOP also interacts directly with AF-2 (L353) and the linker helix (L346 and T350). These results show a strong correlation between the HDX data from the CAR (TCPOBOP) complex displaying regions with significantly reduced exchange kinetics and the CAR ligand-binding pocket in the CAR(TCPOBOP):RXR(9c) structure.

To examine the impact of TCPOBOP binding on the conformational dynamics of RXR within the CAR:RXR heterodimer, we compare the exchange kinetics of all 84 RXR peptides between the CAR:RXR and CAR(TCPOBOP):RXR. Interestingly, we observe that RXR peptides in the region 416–432 display a significant reduction in HDX kinetics in CAR(TCPOBOP):RXR ([Figure 3B](#); [Figure S3B](#)). These amino acids represent a large segment of helix H10 of RXR which forms the dimerization interface between CAR and RXR ([Suino et al., 2004](#)). In summary, residues from both the CAR and RXR dimerization interface display differential exchange kinetics when comparing CAR:RXR with the CAR(TCPOBOP):RXR complex. Taken together, data from HDX and fluorescence titrations suggest that TCPOBOP-binding results in a perturbation of the conformational dynamics within the heterodimer interface as well as conformational changes near the RXR ligand-binding pocket.

We analyzed exchange kinetics for 76 regions of CAR within the CAR(meclizine):RXR and CAR:RXR complexes ([Figure 3C](#); [Figure S3A](#)). Additionally, we compare HDX behavior for 84 regions of RXR within the CAR:RXR and CAR(meclizine):RXR complexes ([Figure S3B](#)). The first of two regions within CAR(meclizine):RXR that are significantly protected to exchange when compared with unliganded CAR:RXR includes a segment of the β sheet and all of helix H6 (residues 228–245). The second protected region of CAR(meclizine):RXR includes helices H10/11 and H12 (residues 327–358) ([Figure 3C](#)). As mentioned previously, helix H10/11 is the major contributor to the dimer interface in CAR:RXR and H12 forms the AF-2 subdomain that is critical to its interactions with SRC1. As predicted by fluorescence quenching experiments ([Figure 2](#)), and in contrast to CAR(TCPOBOP):RXR, there are no significant differences in exchange kinetics in RXR within the CAR(meclizine):RXR and CAR:RXR complexes ([Figure S3B](#)).




Figure 2. TCPOBOP Binding to CAR Results in a Conformational Change in RXR

(A) Change in intrinsic tryptophan fluorescence of RXR is monitored in response to increasing levels of CAR ligand.

(B) TCPOBOP elicits a dose-responsive change in RXR fluorescence while meclizine does not.

See also [Figures S1 and S2](#).




Figure 3. Perturbations in HDX Data for CAR and RXR LBDs

Cartoon rendition of percent reduction in HDX of ligand bound CAR:RXR heterodimer complex relative to unliganded receptor. Increasing protections from deuterium exchange are represented as color gradient from light to dark blue as shown. TCPOBOP is shown as an orange space-filled model.

(A) CAR portion of CAR(TCPOBOP):RXR (76 peptides).

(B) RXR portion of CAR(TCPOBOP):RXR (84 peptides).

(C) CAR portion of the CAR(meclizine):RXR (76 peptides).

(D) Residues within the encircled region in the unliganded CAR LBD model are mutated and tested for activity.

See also Figure S3.

Stabilization of CAR H10/11 Is Proportional to Transactivation and Coactivator Recruitment

Subtle differences in H/D exchange patterns within helices H10–H12, which contains the AF-2 region, are evident between the two ligand complexes. For instance, the C-terminal region of helix H10 (residues 330–338) indicate lesser mobility of CAR(TCPOBOP):RXR (exchange level = –32%) than CAR(meclizine):RXR (exchange level = –10%) (Figure S3A). At the AF2, the most prominent differences between the two liganded complexes are in residues 338–343 preceding the AF2 (helix H12). These residues form a short α helix (H11) in the inverse agonist bound structure of CAR (Moore, 2005) but are part of the longer H10 observed in the CAR(TCPOBOP):RXR structure.

We introduced site-specific mutations within helix H11 to investigate the role of this subdomain on the transactivation of CAR. The CAR Glu339 forms a hydrogen bond with the backbone amide of Gln245, presumably contributing to the stability of the active-state conformation of CAR (Shan et al., 2004). Also, Leu340 and Leu343 extend into the apolar ligand-binding pocket and can form hydrophobic interactions with residues within the interior of the protein. Thus, alanine substitutions of Glu339, Leu340, and Leu343 should eliminate these interactions resulting in a less constrained helix H11. As predicted, we observe that E339A (Shan et al., 2004), L340A and L343A each substantially decreases CAR transactivation in transfected CV-1 cell-based reporter gene assays (Figure 4A). Transactivation by these CAR mutants is rescued by exogenously added TCPOBOP to wild-type agonist-bound levels. We also reason that the substitution of Leu340 and Leu343 with residues capable of stronger apolar interactions with the CAR apolar ligand-binding pocket would constrain helix H11 to a greater extent than wild-type CAR. To test the hypothesis that the mobility of helix H11 can regulate

increased interactions of the bulkier phenylalanine side chain with the apolar CAR ligand-binding pocket. Therefore, stronger interactions between the L340F and L343F on helix H11 and the main body of CAR can reduce the dynamics of this helix, and this corresponds to higher transactivation by these mutants.

To relate the conformational mobility of helix H11 observed by HDX to the transactivation of the CAR helix H11 mutants, we characterized coactivator binding by these CAR mutants. The affinity of (L343A)CAR:RXR for the SRC1 NR box 2 peptide is lower than wild-type CAR, as suggested by the transactivation profile for this mutant (Figures 4B and 4C). Additionally, this mutant displays appreciably higher unfavorable entropy ($T\Delta S$) (Table 2). In the presence of TCPOBOP, the affinity of (L343A)CAR:RXR for the 13-mer SRC1 peptide is comparable to wild-type CAR(TCPOBOP):RXR (Table 2). Again, in close agreement with the transactivation assay, (L343F)CAR:RXR displays significantly greater affinity for coactivator and lower unfavorable entropy compared with the wild-type complex (Table 2). Also, the affinity of (L343F)CAR(androsteno):RXR for the SRC1 peptide is similar to wild-type CAR(androsteno):RXR (Table 2). These results provide further support for the hypothesis that the local dynamics of H11 plays a critical role in regulating CAR transactivation. It is likely that TCPOBOP imparts greater stability to this region and that this provides the structural basis for the higher levels of transactivation and coactivator binding by CAR(TCPOBOP):RXR than by the unliganded CAR:RXR or CAR(meclizine):RXR complexes.

DISCUSSION

Since CAR is active in the unliganded state, displays increased transactivation in the presence of meclizine and highest




Figure 4. Transactivation and Coactivator Binding Assays of CAR:RXR

(A) b) Luciferase reporter assay showing ligand (TCPOBOP) mediated CAR:RXR transactivation of the LXRE-TK-Luc reporter plasmid in CV-1 cells. Results are reported in relative luciferase units (RLU).

(B and C) (B) Binding isotherms from titrations of SRC1 peptide into unliganded (L343A)CAR:RXR and (L343F)CAR:RXR and (C) summary of the SRC1 binding assay.

transactivation in the presence of TCPOBOP, it is an ideal protein to study the relationship of conformational dynamics and activity in NRs. We have compared transcriptional activation, coactivator recruitment, and conformational dynamics of CAR:RXR in the presence of two functionally distinct agonists. Cell-based reporter gene assays and ITC experiments show that TCPOBOP elicits greater transactivation and that this increase is proportional to the difference in affinity for SRC1. Comprehensive analysis of differential HDX behavior of the two ligand-bound forms

clearly shows that the impact of TCPOBOP on the conformational dynamics of the CAR structure is broader and of greater magnitude than that of meclizine. This result is surprising since the two ligands are very similar in molecular size and chemical structure (Figure 1A). It is possible that meclizine does not make as many efficient contacts within the CAR ligand-binding pocket as compared with TCPOBOP or that the CAR(meclizine) complex does not establish the intricate layers of interactions observed in the CAR(TCPOBOP) structure. Additionally, there

Table 2. Thermodynamic Parameters for SRC1 Peptide Binding to the Indicated CAR:RXR Complexes

Complex	K_d (μM)	ΔH (kcal/mol)	$-T\Delta S$ (kcal/mol)	ΔG (kcal/mol)	n
L343A (no ligand)	14 ± 1.7	-10.6 ± 0.5	4.0	-6.6	1.0 ± 0.13
L343A(TCPOBOP)	2.0 ± 0.24	-11.5 ± 0.8	3.7	-7.8	0.92 ± 0.14
L343F(no ligand)	0.92 ± 0.05	-8.5 ± 0.2	0.30	-8.2	0.97 ± 0.05
L343F (androst-enol)	4.2 ± 0.29	-10.0 ± 0.2	2.7	-7.3	1.0 ± 0.04

Determined at 25°C and pH 7.2 as described in [Experimental Procedures](#). The reported values are the average of at least three experiments and the errors are the standard deviation.

are more rotatable bonds within the meclizine structure which can allow it to adapt more readily to the CAR ligand-binding pocket unlike the relatively rigid TCPOBOP which can bind CAR more strongly but can also restrict the dynamics of the protein.


The global HDX kinetics observed for these three complexes shows that the CAR:RXR complex is more dynamic with the rank order of CAR:RXR >> CAR(meclizine):RXR > CAR(TCPOBOP):RXR, and that it follows the same pattern as the values for $T\Delta S$ observed upon binding the LXXLL coactivator peptide (Table 1). This parallel suggests that, globally, the higher affinity for SRC1 results from a reduction in unfavorable entropy. The binding of the ligand TCPOBOP (and to a lesser extent meclizine) restricts the conformational dynamics of the protein. Thus, coactivator binding is accompanied by a smaller net change in dynamics of CAR and a smaller positive $T\Delta S$ component to the interaction. Since ΔS values depend on other factors in addition to degrees of freedom of the polypeptide chain (e.g., solvent reorganization), any correlation between ΔS and dynamics must include these factors. Nonetheless, the coactivator peptide binding and HDX data when taken together suggest that the overall reduction in protein motion is correlated with higher affinity for SRC-1 by CAR:RXR.

Besides the global properties observed, there are two specific areas of difference in the HDX data that distinguish TCPOBOP from meclizine. First, the binding of TCPOBOP to CAR also impacts the dynamics of RXR in CAR:RXR. This is not surprising given the large conformational changes in the CAR helix H10 which forms a significant portion of the heterodimer interface. Second, the greatly reduced HDX kinetics within helix H10/11 in CAR(TCPOBOP):RXR and the data from mutagenesis studies of residues within this region show that reducing mobility of this helix is a key component of the increase in activity by CAR agonist. Observations that regions within the LBD other than AF-2 can be major determinants of coactivator affinity and transactivation levels have been reported previously in the androgen receptor (Estebanez-Perpina et al., 2007), estrogen receptor (Dai et al., 2008), and PPAR γ (Bruning et al., 2007; Choi et al., 2010).

The HDX and H11 mutagenesis data also provide insight into the structure of unliganded CAR:RXR (which has not been reported) as well as dynamic and conformational changes associated with the transitions between the active and very active states of CAR. The relatively shorter H12 in CAR compared with other NRs and the resulting interaction between the C-terminal carbonyl interacting with the side chain of K205 (Dussault et al., 2002) is understood to position helix H12 in the active position in the unliganded protein resulting in its constitu-

tive activity. This helix H12 conformation is retained in the CAR (TCPOBOP) complex (Suino et al., 2004). In the presence of the inverse agonist, androst-enol, helix H10 dissociated into two helices with the C-terminal residues (338–343) forming the short H11 (Shan et al., 2004). The significant differences in mobility observed in the H/D exchange data for residues 338–343 suggest that in the unliganded state H10 may more closely resemble the CAR(androst-enol) structure with a shorter, more mobile, helix H11. Thus, unliganded, active CAR may have a conformation that contains a short H11 similar to the inactive CAR(androst-enol) structure but with helix H12 in an orientation similar to the very active CAR(TCPOBOP) conformation (Figure 5). In the CAR(TCPOBOP):RXR complex helices H10 and H11 fuse into a single helix H10. The L340F and L343F CAR mutants appear to mimic TCPOBOP in stabilizing helix H11 which leads to enhanced coactivator recruitment and increases the levels of CAR transactivation.

In summary, these results provide insight into the mechanism of graded modulation of CAR activity for structurally similar agonists. It remains to be determined whether these mechanisms are common to other NRs or unique to a subset of NR family members. For instance, studies on the estrogen receptor have indicated that allosteric communication between dimeric partners can be mediated via helix H11 (Nettles et al., 2004). More importantly, these results provide the foundation for designing compounds that target CAR with varying degrees of agonist activity.

**Figure 5. Comparison of CAR LBD Structures**

(A) Structure of the CAR(androst-enol) complex (REF). (B) Proposed model for the structure of unliganded CAR based on the HDX data and site-directed mutagenesis studies for residues 338–343. (C) Structure of the CAR(TCPOBOP) complex (REF). The circled regions have different conformations in the CAR(androst-enol) and CAR(TCPOBOP) structures. Ligands are shown in mesh format.

EXPERIMENTAL PROCEDURES

Protein Expression and Purification

Protein was prepared as described previously (Wright et al., 2007). In brief, the mCAR LBD (residues 117–358) was subcloned into pET15b (Novagen) with an N-terminal hexahistidine tag from mCAR cDNA provided by B. M. Forman. The human RXR LBD (residues 225–462) in pACYC184 was a gift from B. Wisely (Glaxo Smith-Kline, Inc.). The plasmids of CAR and RXR were cotransformed into *Escherichia coli* BL21(DE3) Gold cells (Novagen) and coexpressed for 20 hr at 20°C after induction with 0.5 mM IPTG. The cells were lysed by French press. The CAR:RXR heterodimer was purified by affinity chromatography using Ni-NTA (QIAGEN) followed by size-exclusion chromatography on a Superdex S75 column (GE Healthcare). The mobile phase for size-exclusion chromatography consisted of 20 mM Tris-HCl buffer (pH 8.0), 250 mM NaCl, 2.5 mM EDTA, 5.0 mM DTT for fluorescence and HDX experiments and 50 mM HEPES (pH 7.5), 125 mM KCl, and 2 mM TCEP for ITC experiments.

Reporter Gene Assays

CV-1 cells were maintained in DMEM/F-12 media containing 10% fetal bovine serum and 1000 U/ml penicillin and 1 mg/ml streptomycin. Immediately prior to the assay, the media was changed to DMEM/F-12 with 10% charcoal-dextran treated FBS and no antibiotics. Lipofectamine (Invitrogen) was used to transfect cells with 50 ng/well pCMX mCAR, 100 ng/well pCMV-TK-luc containing three copies of either retinoid acid receptor β 2 response element (β RE) or liver X receptor response element (LXRE) and 25 ng of pRL CMV expressing renilla luciferase as an internal control. The cells were dispensed on 96-well plates and ligands were added 4 hours after transfection. The ligand concentrations used were TCPOBOP (1.0 μ M), androstrenol (10 μ M), and meclizine (20 μ M). After 36 hr, cells were lysed. Activity was determined using the dual luciferase assay kit (Promega) following the manufacturer's instructions. The reported results are the average from three separate experiments and the error bars represent the standard deviation.

Isothermal Titration Calorimetry

Experiments were performed as described previously using the Microcal VP-ITC instrument (Wright et al., 2007). In brief, 100–400 μ M SRC1 box 2 peptide was titrated into 8–36 μ M CAR:RXR LBDs in 50 mM HEPES (pH 7.4), 125 mM KCl, and 1 mM TCEP. A 4-fold excess of TCPOBOP or a 10-fold excess of meclizine was included where indicated. Data were analyzed using the one-site binding model in the Origin 7.0 software provided with the instrument. The reported results are the average from four separate experiments and the error bars represent the standard deviation.

Hydrogen/Deuterium Exchange Analysis

Solution phase amide HDX was performed on liganded and unliganded CAR:RXR LBD heterodimers using a fully automated system that is described elsewhere (Busby et al., 2007; Chalmers et al., 2006). The changes reported in HDX are from direct comparisons between CAR(ligand):RXR to the corresponding regions within the unliganded CAR:RXR. In brief, 4 μ l of a 10 μ M protein solution containing either the copurified, preformed CAR:RXR heterodimer or CAR:RXR bound to either meclizine or TCPOBOP (20 mM Tris-Cl [pH 8], 250 mM NaCl, 5 mM DTT) was diluted up to 20 μ l with D₂O dilution buffer (20 mM Tris-Cl [pH 8], 250 mM NaCl, 5 mM DTT) and incubated at 4°C for the following periods of time: 10, 30, 60, 300, 900, and 3600 s. Following deuterium on-exchange, unwanted forward and back exchange was minimized and the protein was denatured by dilution to 50 μ l with 1% TFA in 3 M Urea (held at 1°C). The protein sample was then passed across an immobilized pepsin column (prepared in house) at 200 μ l/min (0.1% TFA, 1°C) and the resulting peptides were trapped onto a C₁₈ trap column (Microm Bioresources). Peptides were gradient eluted (4% CH₃CN to 40% CH₃CN, 0.3% formic acid over 15 min at 2°C) over a 2.1 mm \times 50 mm C₁₈ reverse phase HPLC column (Hypersil Gold, Thermo Electron) and electrosprayed directly into a high resolution orbitrap mass spectrometer (LTQ-Exactive, ThermoElectron, San Jose CA). Data were processed using in-house software (Pascal et al., 2006, 2007, 2009) and Microsoft Excel followed by visualization with pyMol (DeLano Scientific, South San Francisco CA). For the differential analysis between the unliganded and meclizine bound forms of the CAR:RXR, average percent deuterium incorporation was calculated for 76 regions of the

CAR portion and 84 regions of the RXR portion of the CAR:RXR heterodimer in either its unliganded or meclizine bound state following 10, 30, 60, 300, 900, and 3600 s of on-exchange with deuterium. In addition, for the differential analysis between the unliganded and TCPOBOP bound forms of the CAR:RXR, average percent deuterium incorporation was calculated for 76 regions of the CAR and 84 regions of RXR in either its liganded or TCPOBOP bound state following 10, 30, 60, 300, 900, and 3600 s of on-exchange with deuterium. To determine differences in exchange between the CAR portions of the unliganded and the ligand bound CAR:RXR, the average percent deuterium values for all regions of the CAR from the unliganded CAR:RXR heterodimer were subtracted from the average percent deuterium values of the identical CAR regions from the CAR:RXR heterodimer bound to either meclizine or TCPOBOP. The same procedure was used to determine differences in exchange between the RXR portions of the heterodimer in either its unliganded or ligand bound states.

Ligand Binding Assays

Binding was measured by monitoring the decrease in intrinsic tryptophan fluorescence upon addition of ligand. For binding of CAR ligands, protein was diluted to a concentration of 2.0 μ M with fluorescence buffer (3% DMSO, 20 mM Tris-HCl [pH 8.0], 150 mM NaCl). Protein was then degassed for 15 min. Titrations were performed on the Perkin Elmer LS55 spectrofluorometer. Scans were performed using an excitation wavelength of 295 nm and emission scan of 305–400 nm. The excitation and emission slit widths were 8.0 nm. Either DMSO or ligand was added in 2 μ l increments into a 2.5 ml protein solution. Titrations of 9-cis-retinoic acid (9c) into CAR:RXR were performed in a similar manner except a protein concentration of 0.5 μ M was used and the excitation and emission slit widths were 4.0 nm. Control experiment titrating TCPOBOP and meclizine into 2.0 μ M molecular tryptophan showed no effect on fluorescence.

SUPPLEMENTAL INFORMATION

Supplemental Information includes three figures and can be found with this article online at doi:10.1016/j.str.2010.11.008.

ACKNOWLEDGMENTS

This work is supported by National Institutes of Health Grant DK066394 (E.J.F.)

Received: September 23, 2010

Revised: November 9, 2010

Accepted: November 13, 2010

Published: January 11, 2011

REFERENCES

- Baes, M., Gulick, T., Choi, H.S., Martinoli, M.G., Simha, D., and Moore, D.D. (1994). A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements. *Mol. Cell. Biol.* 14, 1544–1551.
- Bourguet, W., Germain, P., and Gronemeyer, H. (2000). Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. *Trends Pharmacol. Sci.* 21, 381–388.
- Bruning, J.B., Chalmers, M.J., Prasad, S., Busby, S.A., Kamenecka, T.M., He, Y., Nettles, K.W., and Griffin, P.R. (2007). Partial agonists activate PPARgamma using a helix 12 independent mechanism. *Structure* 15, 1258–1271.
- Busby, S.A., Chalmers, M.J., and Griffin, P.R. (2007). Improving digestion efficiency under H/D exchange conditions with activated pepsinogen coupled columns. *Int. J. Mass Spectrom.* 259, 130–139.
- Chalmers, M.J., Busby, S.A., Pascal, B.D., He, Y., Hendrickson, C.L., Marshall, A.G., and Griffin, P.R. (2006). Probing protein ligand interactions by automated hydrogen/deuterium exchange mass spectrometry. *Anal. Chem.* 78, 1005–1014.
- Chang, T.K., and Waxman, D.J. (2006). Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR). *Drug Metab. Rev.* 38, 51–73.

- Choi, H.S., Chung, M., Tzamelis, I., Simha, D., Lee, Y.K., Seol, W., and Moore, D.D. (1997). Differential transactivation by two isoforms of the orphan nuclear hormone receptor CAR. *J. Biol. Chem.* *272*, 23565–23571.
- Choi, J.H., Banks, A.S., Estall, J.L., Kajimura, S., Bostrom, P., Laznik, D., Ruas, J.L., Chalmers, M.J., Kamenecka, T.M., Bluher, M., et al. (2010). Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. *Nature* *466*, 451–456.
- Dai, S.Y., Chalmers, M.J., Bruning, J., Bramlett, K.S., Osborne, H.E., Montrose-Rafizadeh, C., Barr, R.J., Wang, Y., Wang, M., Burris, T.P., et al. (2008). Prediction of the tissue-specificity of selective estrogen receptor modulators by using a single biochemical method. *Proc. Natl. Acad. Sci. USA* *105*, 7171–7176.
- Dussault, I., Lin, M., Hollister, K., Fan, M., Termini, J., Sherman, M.A., and Forman, B.M. (2002). A structural model of the constitutive androstane receptor defines novel interactions that mediate ligand-independent activity. *Mol. Cell. Biol.* *22*, 5270–5280.
- Estebanez-Perpina, E., Arnold, L.A., Nguyen, P., Rodrigues, E.D., Mar, E., Bateman, R., Pallai, P., Shokat, K.M., Baxter, J.D., Guy, R.K., et al. (2007). A surface on the androgen receptor that allosterically regulates coactivator binding. *Proc. Natl. Acad. Sci. USA* *104*, 16074–16079.
- Forman, B.M., Tzamelis, I., Choi, H.S., Chen, J., Simha, D., Seol, W., Evans, R.M., and Moore, D.D. (1998). Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta. *Nature* *395*, 612–615.
- Gangloff, M., Ruff, M., Eiler, S., Duclaud, S., Wurtz, J.M., and Moras, D. (2001). Crystal structure of a mutant hERalpha ligand-binding domain reveals key structural features for the mechanism of partial agonism. *J. Biol. Chem.* *276*, 15059–15065.
- Glass, C.K., Rose, D.W., and Rosenfeld, M.G. (1997). Nuclear receptor coactivators. *Curr. Opin. Cell Biol.* *9*, 222–232.
- Huang, W., Zhang, J., Chua, S.S., Qatanani, M., Han, Y., Granata, R., and Moore, D.D. (2003). Induction of bilirubin clearance by the constitutive androstane receptor (CAR). *Proc. Natl. Acad. Sci. USA* *100*, 4156–4161.
- Huang, W., Zhang, J., Wei, P., Schrader, W.T., and Moore, D.D. (2004). Meclizine is an agonist ligand for mouse constitutive androstane receptor (CAR) and an inverse agonist for human CAR. *Mol. Endocrinol.* *18*, 2402–2408.
- Huang, W., Zhang, J., Washington, M., Liu, J., Parant, J.M., Lozano, G., and Moore, D.D. (2005). Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. *Mol. Endocrinol.* *19*, 1646–1653.
- Mangelsdorf, D.J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., and Evans, R.M. (1995). The nuclear receptor superfamily: the second decade. *Cell* *83*, 835–839.
- Moore, D.D. (2005). CAR: three new models for a problem child. *Cell Metab.* *1*, 6–8.
- Moras, D., and Gronemeyer, H. (1998). The nuclear receptor ligand-binding domain: structure and function. *Curr. Opin. Cell Biol.* *10*, 384–391.
- Nettles, K.W., Sun, J., Radek, J.T., Sheng, S., Rodriguez, A.L., Katzenellenbogen, J.A., Katzenellenbogen, B.S., and Greene, G.L. (2004). Allosteric control of ligand selectivity between estrogen receptors alpha and beta: implications for other nuclear receptors. *Mol. Cell* *13*, 317–327.
- Oberfield, J.L., Collins, J.L., Holmes, C.P., Goreham, D.M., Cooper, J.P., Cobb, J.E., Lenhard, J.M., Hull-Ryde, E.A., Mohr, C.P., Blanchard, S.G., et al. (1999). A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. *Proc. Natl. Acad. Sci. USA* *96*, 6102–6106.
- Pascal, B., Chalmers, M.J., Busby, S.A., Southern, M., Mader, C., Griffin, P., and Tsinoremas, N. (2006). Software for the calculation of backbone amide deuterium levels from H/D exchange MS data. *Mol. Cell. Proteomics* *5*, S90–S90.
- Pascal, B.D., Chalmers, M.J., Busby, S.A., Mader, C.C., Southern, M.R., Tsinoremas, N.F., and Griffin, P.R. (2007). The Deuterator: software for the determination of backbone amide deuterium levels from H/D exchange MS data. *BMC Bioinformatics* *8*, 156.
- Pascal, B.D., Chalmers, M.J., Busby, S.A., and Griffin, P.R. (2009). HD desktop: an integrated platform for the analysis and visualization of H/D exchange data. *J. Am. Soc. Mass Spectrom.* *20*, 601–610.
- Shan, L., Vincent, J., Brunzelle, J.S., Dussault, I., Lin, M., Ianculescu, I., Sherman, M.A., Forman, B.M., and Fernandez, E.J. (2004). Structure of the murine constitutive androstane receptor complexed to androstenol: a molecular basis for inverse agonism. *Mol. Cell* *16*, 907–917.
- Sonoda, J., Rosenfeld, J.M., Xu, L., Evans, R.M., and Xie, W. (2003). A nuclear receptor-mediated xenobiotic response and its implication in drug metabolism and host protection. *Curr. Drug Metab.* *4*, 59–72.
- Suino, K., Peng, L., Reynolds, R., Li, Y., Cha, J.Y., Repa, J.J., Kliewer, S.A., and Xu, H.E. (2004). The nuclear xenobiotic receptor CAR; structural determinants of constitutive activation and heterodimerization. *Mol. Cell* *16*, 893–905.
- Tzamelis, I., Pissios, P., Schuetz, E.G., and Moore, D.D. (2000). The xenobiotic compound 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene is an agonist ligand for the nuclear receptor CAR. *Mol. Cell. Biol.* *20*, 2951–2958.
- Wei, P., Zhang, J., Egan-Hafley, M., Liang, S., and Moore, D.D. (2000). The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. *Nature* *407*, 920–923.
- Wright, E., Vincent, J., and Fernandez, E.J. (2007). Thermodynamic characterization of the interaction between CAR-RXR and SRC-1 peptide by isothermal titration calorimetry. *Biochemistry* *46*, 862–870.
- Wurtz, J.M., Bourguet, W., Renaud, J.P., Vivat, V., Chambon, P., Moras, D., and Gronemeyer, H. (1996). A canonical structure for the ligand-binding domain of nuclear receptors. *Nat. Struct. Biol.* *3*, 87–94.